Current treatment of acute myeloid leukemia by targeting leukemia stem cells / 白血病·淋巴瘤

ABSTRACT

Acute myeloid leukemia (AML) originates from rare leukemia stem cells (LSC).Because these chemotherapy-resistant LSC are thought to underlie disease relapse,effective therapeutic strategies specifically targeting these cells may be beneficial.With the increasing knowledge regarding the LSC,several major directions in targeted therapies with regard to LSC are being investigated.These include targeting cell surface molecules,signal pathways,and microenvironment of LSC.Since eliminating LSC-should provide an efficient,potentially curative treatment option for leukemia patients,this article reviews the recent progress of LSC targeting in AML therapy.